1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,304 | 0,496 | 05.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.02. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION PLAN OF THE COMPANY | 1 | HKEx | ||
| 30.01. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION PLAN OF THE COMPANY | 1 | HKEx | ||
| JIANGSU RECBIO TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 29.12.25 | RECBIO-B (02179): VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF THE NEW DRUG APPLICATION FOR THE COMPANY'S NOVEL ADJUVANTED RECOMBINANT SHINGLES VACCINE REC610 ... | 2 | HKEx | ||
| 23.12.25 | RECBIO-B (02179): CHANGE OF THE CHAIRMAN OF THE BOARD OF DIRECTORS AND ADJUSTMENT TO THE COMPOSITION OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): RULES OF PROCEDURE FOR THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): RULES OF PROCEDURE FOR THE GENERAL MEETINGS | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 19, 2025; AMENDMENTS TO THE ARTICLES OF ASSOCIATION; ABOLISHMENT ... | 1 | HKEx | ||
| 17.12.25 | RECBIO-B (02179): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 17.12.25 | RECBIO-B (02179): ANNOUNCEMENT IN RELATION TO COMPLETION OF THE ISSUANCE OF DOMESTIC SHARES | 2 | HKEx | ||
| 01.12.25 | RECBIO-B (02179): FORM OF PROXY FOR USE AT THE 2025 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, DECEMBER 19, 2025 | - | HKEx | ||
| 01.12.25 | RECBIO-B (02179): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 01.12.25 | RECBIO-B (02179): PROPOSED ABOLISHMENT OF THE SUPERVISORY BOARD AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ITS ATTACHMENTS; PROPOSED ELECTION OF ... | - | HKEx | ||
| 01.12.25 | RECBIO-B (02179): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD | 3 | HKEx | ||
| 01.12.25 | RECBIO-B (02179): TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE OF THE BOARD | - | HKEx | ||
| 01.12.25 | RECBIO-B (02179): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD | 1 | HKEx | ||
| 01.12.25 | RECBIO-B (02179): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 01.12.25 | RECBIO-B (02179): RESIGNATION OF DIRECTORS, AUTHORISED REPRESENTATIVE AND JOINT COMPANY SECRETARY, PROPOSED APPOINTMENT OF DIRECTORS, APPOINTMENT OF AUTHORISED ... | - | HKEx | ||
| 25.11.25 | RECBIO-B (02179): ARTICLES OF ASSOCIATION | 1 | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,550 | -0,80 % | Shortseller-Positionen aktuell: freenet, Gerresheimer, Hypoport, Qiagen, Renk, Suss MicroTec, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| TANGO THERAPEUTICS | 16,820 | 0,00 % | Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat | ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO... ► Artikel lesen | |
| BIONTECH | 87,65 | -1,74 % | BioNTech Aktie: Die Wende naht! Golden Cross! | © Foto: 2026 BioNTech SE. Alle Recht vorbehalten.Fast wie in der Serie "Game of Thrones", wo der Winter naht, könnte bei BioNTech die Wende nahen. Nach dem Kursrausch in der Corona-Ära folgte der brutale... ► Artikel lesen | |
| ARCELLX | 114,36 | +0,09 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| MODERNA | 46,500 | -6,38 % | Moderna: Kombi-Impfung für Grippe und Covid erhält Zulassung | Gute Nachrichten für Moderna: Die EU-Arzneimittelbehörde EMA hat grünes Licht gegeben für den ersten Kombi-Impfstoff gegen Corona und Grippe. Der Wirkstoff solle für Menschen ab 50 Jahren zugelassen... ► Artikel lesen | |
| ERASCA | 15,560 | +2,91 % | Clear Street raises Erasca stock price target on combination trial deal | ||
| TYRA BIOSCIENCES | 34,550 | -1,96 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| CG ONCOLOGY | 60,35 | -1,87 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,96 | -1,79 % | RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook | ||
| ADMA BIOLOGICS | 15,700 | -5,11 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| EVOTEC | 5,464 | -3,33 % | Evotec Aktie vor dem Durchbruch? Diesmal ist etwas anders... | Die Evotec Aktie hat zuletzt ein wichtiges Muster bestätigt: Wiederholt scheiterte die Biotech-Aktie aus Hamburg mit Breakversuchen an der 200-Tage-Linie. Nach mehr oder weniger starken Ausbrüchen hierüber... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,520 | 0,00 % | Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) | New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,450 | +1,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 28,510 | -0,31 % | UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry | ||
| MINERALYS THERAPEUTICS | 26,700 | -7,29 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen |
JIANGSU RECBIO TECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,462 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JIANGSU RECBIO TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.